{"id":"albumin-paclitaxel-cispatin-tislelizumab","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Neutropenia"},{"rate":"10-30%","effect":"Anemia"},{"rate":"10-20%","effect":"Thrombocytopenia"},{"rate":"20-40%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-20%","effect":"Rash"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Albumin paclitaxel uses albumin as a carrier to deliver paclitaxel to tumors, reducing systemic toxicity. Tislelizumab targets the PD-1 receptor on T cells, preventing its interaction with PD-L1 on tumor cells and allowing the immune system to attack cancer cells more effectively. Cisplatin works by forming platinum-DNA adducts that interfere with DNA replication and transcription, leading to cell death.","oneSentence":"Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:20.981Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer, gastric cancer, esophageal cancer"}]},"trialDetails":[{"nctId":"NCT06258811","phase":"PHASE3","title":"Neoadjuvant Immunochemotherapy for LAOSCC","status":"RECRUITING","sponsor":"Lai-ping Zhong","startDate":"2024-02-20","conditions":"Oral Squamous Cell Carcinoma, Locally Advanced Head and Neck Carcinoma","enrollment":134}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"albumin paclitaxel, cispatin, tislelizumab","genericName":"albumin paclitaxel, cispatin, tislelizumab","companyName":"Lai-ping Zhong","companyId":"lai-ping-zhong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication. Used for Non-small cell lung cancer, gastric cancer, esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}